Literature DB >> 12496414

Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.

Julia K Voice1, Carola Grinninger, Yvonne Kong, Yogesh Bangale, Sudhir Paul, Edward J Goetzl.   

Abstract

Vasoactive intestinal peptide (VIP) and its two G protein-coupled receptors, VPAC1 and VPAC2, are quantitatively prominent and functionally critical in the immune system. Transgenic (T) mice constitutively expressing VPAC2 selectively in CD4 T cells, at levels higher than those found after maximal induction in CD4 T cells of wild-type (N) mice, have elevated blood concentrations of IgE, IgG1, and eosinophils; enhanced immediate-type hypersensitivity; and reduced delayed-type hypersensitivity. In contrast, VPAC2-null (K) mice manifest decreased immediate-type hypersensitivity and enhanced delayed-type hypersensitivity. The phenotypes are attributable to opposite skewing of the Th2/Th1 cytokine ratio, but no studies were conducted on the roles of T cell-derived VIP and altered expansion of the Th subsets. Dependence of the Th phenotype of T mice, but not of N or K mice, on T cell-derived VIP now is proven by showing that eliminating VIP from TCR-stimulated T cell cultures with VIPase IgG normalizes the elevated number of IL-4-secreting CD4 T cells, decreases the secretion of IL-4 and IL-10, and increases the secretion of IFN-gamma. Flexible responsiveness of CD4 T cells from N and K mice, but not T mice, to exogenous VIP in vitro and in vivo is shown by increased numbers of IL-4-secreting CD4 T cells, greater secretion of IL-4 and IL-10, and lesser secretion of IFN-gamma after TCR stimulation with VIP. The level of VIP recognized by CD4 T cells thus is a major determinant of the relative contributions of Th subsets to the immune effector phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12496414     DOI: 10.4049/jimmunol.170.1.308

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

Review 2.  Antimicrobial anxiety: the impact of stress on antimicrobial immunity.

Authors:  Katherine A Radek
Journal:  J Leukoc Biol       Date:  2010-05-04       Impact factor: 4.962

Review 3.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Signaling through the neuropeptide GPCR PAC₁ induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor.

Authors:  Andrew C Emery; Lee E Eiden
Journal:  FASEB J       Date:  2012-04-24       Impact factor: 5.191

5.  Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis.

Authors:  Catalina Abad; Yossan-Var Tan; Robert Lopez; Hiroko Nobuta; Hongmei Dong; Phu Phan; Ji-Ming Feng; Anthony T Campagnoni; James A Waschek
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-26       Impact factor: 11.205

6.  A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

Authors:  Li Liu; Jui-Hung Yen; Doina Ganea
Journal:  Peptides       Date:  2007-03-31       Impact factor: 3.750

Review 7.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

8.  The effect of SCF and ouabain on small intestinal motility dysfunction induced by gastric cancer peritoneal metastasis.

Authors:  Dan Kong; Jing Li; Baoshan Zhao; Bairong Xia; Lei Zhang; Yan He; Xiuli Wang; Lei Gao; Yufu Wang; Xiaoming Jin; Ge Lou
Journal:  Clin Exp Metastasis       Date:  2015-02-19       Impact factor: 5.150

9.  Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors.

Authors:  S A Tannu; L M Renzetti; N Tare; J D Ventre; D Lavelle; T A Lin; A Morschauser; J Paciorek; D R Bolin; H Michel; L Singer; M Hargaden; Id Knowles; P Gardiner; M Cazzola; L Calzetta; M G Matera; A Hicks
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 10.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.